Royalty Pharma annual operating income
2018
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma Operating Income Growth & History (RPRX)
Royalty Pharma's operating income was $1.56B for fiscal 2025.
View full Royalty Pharma company overviewRoyalty Pharma annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.56B | $267.1M | +20.66% |
| 2024 | 2024-12-31 | $1.29B | −$199.7M | −13.38% |
| 2023 | 2023-12-31 | $1.49B | $1.19B | +385.94% |
| 2022 | 2022-12-31 | $307.1M | −$1.12B | −78.54% |
| 2021 | 2021-12-31 | $1.43B | −$164.7M | −10.32% |
| 2020 | 2020-12-31 | $1.60B | −$1.03B | −39.18% |
| 2019 | 2019-12-31 | $2.62B | $1.26B | +92.25% |
| 2018 | 2018-12-31 | $1.36B | — | — |
Royalty Pharma quarterly operating income
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $133.1M | −$76.7M | −36.55% |
| Q1 2026 | 2026-03-31 | $563.0M | $28.9M | +5.40% |
| Q4 2025 | 2025-12-31 | $388.4M | $26.9M | +7.43% |
| Q3 2025 | 2025-09-30 | $427.2M | −$307.9M | −41.89% |
| Q2 2025 | 2025-06-30 | $209.8M | −$59.8M | −22.19% |
| Q1 2025 | 2025-03-31 | $534.2M | $608.0M | — |
| Q4 2024 | 2024-12-31 | $361.5M | −$251.4M | −41.02% |
| Q3 2024 | 2024-09-30 | $735.1M | $583.6M | +385.38% |
| Q2 2024 | 2024-06-30 | $269.6M | $20.8M | +8.35% |
| Q1 2024 | 2024-03-31 | −$73.8M | −$552.7M | — |
| Q4 2023 | 2023-12-31 | $612.9M | $1.10B | — |
| Q3 2023 | 2023-09-30 | $151.4M | −$40.8M | −21.21% |
| Q2 2023 | 2023-06-30 | $248.8M | −$129.0M | −34.13% |
| Q1 2023 | 2023-03-31 | $479.0M | $259.3M | +117.99% |
| Q4 2022 | 2022-12-31 | −$482.7M | −$636.1M | — |
| Q3 2022 | 2022-09-30 | $192.2M | −$110.8M | −36.58% |
| Q2 2022 | 2022-06-30 | $377.8M | −$367.2M | −49.29% |
| Q1 2022 | 2022-03-31 | $219.7M | −$9.6M | −4.18% |
| Q4 2021 | 2021-12-31 | $153.4M | — | — |
| Q3 2021 | 2021-09-30 | $303.1M | −$207.5M | −40.64% |
| Q2 2021 | 2021-06-30 | $744.9M | $335.6M | +81.99% |
| Q1 2021 | 2021-03-31 | $229.3M | −$132.1M | −36.56% |
| Q3 2020 | 2020-09-30 | $510.6M | −$21.9M | −4.12% |
| Q2 2020 · Jun 30 | 2020-06-30 | $409.3M | $81.5M | +24.85% |
| Q1 2020 | 2020-03-31 | $361.4M | — | — |
| Q3 2019 | 2019-09-30 | $532.5M | — | — |
| Q2 2019 | 2019-06-30 | $327.9M | — | — |
Royalty Pharma operating income trends
Over the last five fiscal years, Royalty Pharma's operating income decreased from $1.60B to $1.56B, a change of −$35.9M. The latest reported quarter, Q2 2026, shows $133.1M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Royalty Pharma source filings ↗